Insider Selling: Cerus Co. (NASDAQ:CERS) CEO Sells $91,476.00 in Stock

Cerus Co. (NASDAQ:CERS) CEO William Mariner Greenman sold 60,984 shares of Cerus stock in a transaction on Friday, March 7th. The stock was sold at an average price of $1.50, for a total transaction of $91,476.00. Following the sale, the chief executive officer now owns 4,309,758 shares in the company, valued at $6,464,637. This represents a 1.40 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

William Mariner Greenman also recently made the following trade(s):

• On Tuesday, March 4th, William Mariner Greenman sold 23,023 shares of Cerus stock. The shares were sold at an average price of $1.55, for a total transaction of $35,685.65.

Cerus Stock Down 0.7 %

Shares of NASDAQ:CERS opened at $1.48 on Thursday. The company has a market cap of $274.97 million, a price-to-earnings ratio of -13.45 and a beta of 1.56. The firm’s 50-day simple moving average is $1.73 and its 200-day simple moving average is $1.78. The company has a quick ratio of 1.92, a current ratio of 2.59 and a debt-to-equity ratio of 1.19. Cerus Co. has a fifty-two week low of $1.38 and a fifty-two week high of $2.54.

Cerus (NASDAQ:CERS) last released its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.01) EPS for the quarter, hitting analysts’ consensus estimates of ($0.01). The firm had revenue of $50.81 million for the quarter, compared to the consensus estimate of $50.81 million. Cerus had a negative net margin of 11.60% and a negative return on equity of 40.55%. As a group, equities research analysts predict that Cerus Co. will post -0.08 earnings per share for the current year.

Institutional Trading of Cerus

Institutional investors have recently added to or reduced their stakes in the stock. Rockport Wealth LLC purchased a new stake in Cerus during the fourth quarter worth about $25,000. Cibc World Markets Corp acquired a new position in shares of Cerus in the fourth quarter valued at approximately $26,000. R Squared Ltd acquired a new position in shares of Cerus in the fourth quarter valued at approximately $29,000. Virtu Financial LLC acquired a new position in shares of Cerus in the fourth quarter valued at approximately $33,000. Finally, Dark Forest Capital Management LP acquired a new position in shares of Cerus in the fourth quarter valued at approximately $34,000. Hedge funds and other institutional investors own 78.37% of the company’s stock.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $4.00 target price on shares of Cerus in a report on Friday, February 21st.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.